Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Mignot

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
American Journal of Clinical Oncology|July 28, 2001
Gastric metastases from breast cancer: a retrospective series of 12 patientsL Zelek, P H Cottu, L Mignot, et al.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|January 1, 1987
[Value of initial chemotherapy in the treatment of advanced cancers of the uterine cervix]P Payraudeau-Daoud, N Ciraru-Vigneron, G Bercau, et al.
Seminars in Oncology|August 1, 1995
Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancerV Dieras, M Marty, N Tubiana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group methodV Dieras, J M Extra, E Bellissant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2020
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancerP H Cottu, J Asselah, M Lae, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2008
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancerP H Cottu, J Asselah, M Lae, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1994
High-dose interleukin-2 two days a week for metastatic renal cell carcinoma: a FNCLCC multicenter studyB Escudier, A Ravaud, M Fabbro, et al.
Bulletin Du Cancer|July 1, 1993
[Treatment of advanced breast cancer in postmenopausal women with droloxifene: results of a double-blind phase II trial for dose determination]B Chevallier, M Spielmann, M Marty, et al.
Presse Medicale (Paris, France : 1983)|November 8, 1986
[Pregnancy after treated breast cancer. Results of a case-control study]L Mignot, F Morvan, J Berdah, et al.
Pathologie-Biologie|November 1, 1992
[Intraperitoneal recombinant gamma interferon (RU 42369) efficacy in ovarian carcinomas. European BRM Study Group]J P Guastalla, E Pujade-Lauraine, N Colombo, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
American Journal of Clinical Oncology|July 28, 2001
Gastric metastases from breast cancer: a retrospective series of 12 patientsL Zelek, P H Cottu, L Mignot, et al.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|January 1, 1987
[Value of initial chemotherapy in the treatment of advanced cancers of the uterine cervix]P Payraudeau-Daoud, N Ciraru-Vigneron, G Bercau, et al.
Seminars in Oncology|August 1, 1995
Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancerV Dieras, M Marty, N Tubiana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group methodV Dieras, J M Extra, E Bellissant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2020
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancerP H Cottu, J Asselah, M Lae, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2008
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancerP H Cottu, J Asselah, M Lae, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1994
High-dose interleukin-2 two days a week for metastatic renal cell carcinoma: a FNCLCC multicenter studyB Escudier, A Ravaud, M Fabbro, et al.
Bulletin Du Cancer|July 1, 1993
[Treatment of advanced breast cancer in postmenopausal women with droloxifene: results of a double-blind phase II trial for dose determination]B Chevallier, M Spielmann, M Marty, et al.
Presse Medicale (Paris, France : 1983)|November 8, 1986
[Pregnancy after treated breast cancer. Results of a case-control study]L Mignot, F Morvan, J Berdah, et al.
Pathologie-Biologie|November 1, 1992
[Intraperitoneal recombinant gamma interferon (RU 42369) efficacy in ovarian carcinomas. European BRM Study Group]J P Guastalla, E Pujade-Lauraine, N Colombo, et al.
Pageof 8